APM
BTAI icon

Avidity Partners Management’s BioXcel Therapeutics BTAI Stock Holding History

Avidity Partners Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,188
Closed -$25.3M – 102
2020
Q4 		$25.3M Buy
34,188
+563
+2% +$439K 0.82% 45
2020
Q3 		$23.3M Buy
33,625
+9,369
+39% +$7.03M 1.08% 29
2020
Q2 		$20.6M Buy
24,256
+11,068
+84% +$7.22M 1.32% 28
2020
Q1 		$4.72M Buy
+13,188
New +$4.74M 0.65% 48

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avidity Partners Management's BTAI Position: Q1 2021 in Review

Avidity Partners Management sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 34,188 shares — an estimated $25.3M sold.

Avidity Partners Management first reported a position in BTAI in Q1 2020 and held it in 4 quarters. The position peaked at $25.3M in Q4 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • Avidity Partners Management reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 34,188 BioXcel Therapeutics shares in Q1 2021, an estimated $25.3M.
  • Avidity Partners Management first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 4 quarters.
  • Avidity Partners Management's BioXcel Therapeutics position peaked at $25.3M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.